A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma
Abstract
Daratumumab, pomalidomide, and dexamethasone (DPd) is an FDA-approved 3rd or later line of therapy for myeloma. However, as there are limited published data on the efficacy of 2nd-line DPd, we conducted a retrospective analysis (n = 33). Herein, we report our center's data for 2nd-line DPd. Our patient population had a high amount of high risk cytogenetics (45.5%). The overall response rate (ORR) was 84.9% with a 1-year Progression Free Survival...
Paper Details
Title
A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma
Published Date
Jun 18, 2021
Journal
Volume
62
Issue
12
Pages
3043 - 3046
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History